We then tested this hypothesis and found that lenvatinib increased AZGP1 expression and inhibited TGF-β1 expression, Smad3 phosphorylation, and EMT-dependent AZGP1 expression in ICC cells by increasing AZGP1 expression. This evidence concerns the gene AZGP1 and intrahepatic cholangiocarcinoma.